Petros Pharmaceuticals Files Definitive Proxy Statement

TL;DR

PETROS files proxy statement, shareholders vote soon.

AI Summary

Petros Pharmaceuticals, Inc. filed a Definitive Proxy Statement (DEF 14A) on October 25, 2024, for its fiscal year ending December 31, 2024. The filing, which does not require a fee, pertains to the company's proxy solicitation activities under the Securities Exchange Act of 1934. The company's principal executive offices are located at 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036.

Why It Matters

This filing is a standard regulatory requirement for public companies, informing shareholders about matters to be voted on at upcoming meetings, such as director elections or executive compensation.

Risk Assessment

Risk Level: low — This is a routine regulatory filing and does not contain new financial information or strategic changes that would immediately impact risk.

Key Players & Entities

• Petros Pharmaceuticals, Inc. (company) — Registrant
• 0001104659-24-111512 (filing_id) — Accession Number
• 20241025 (date) — Filing Date
• 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036 (address) — Company Business Address

FAQ

Key Financial Figures

• $0.0001 — g shares of our common stock, par value $0.0001 per share, at a ratio in the range of 1

Filing Documents

• tm2426177-2_def14a.htm (DEF 14A) — 597KB
• lg_petros-4clr.jpg (GRAPHIC) — 13KB
• px_24petropxy01pg01-bw.jpg (GRAPHIC) — 262KB
• px_24petropxy01pg02-bw.jpg (GRAPHIC) — 266KB
• 0001104659-24-111512.txt ( ) — 1289KB

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 10 Management and Corporate Governance 13 Certain Relationships and Related Person Transactions 21 Executive Officer and Director Compensation 22 Proposal No. 1—Election of Directors 27 Report of Audit Committee 28 Proposal No. 2—Independent Registered Public Accounting Firm 29 Proposal No. 3—Approval, on an Advisory Basis, of the Compensation Paid to Our Named Executive Officers 31 Proposal No. 4 — Approval of the Amendment to the Company's Amended and Restated Certificate of Incorporation to Effect the Reverse Stock Split 32 Proposal No. 5 — Adjournment of the Annual Meeting, if Necessary, to Solicit Additional Proxies if there are Insufficient Votes at the Time of the Annual Meeting to Approve One or More Proposals Presented at the Annual Meeting 40 Other Matters 41 Stockholder Communications to the Board 41 Stockholder Proposals and Nominations for Director 41 Annex A— Certificate of Amendment of Amended and Restated Certificate of Incorporation of Petros Pharmaceuticals, Inc.. A-1 i TABLE OF CONTENTS Petros Pharmaceuticals, Inc. 1185 Avenue of the Americas, 3rd Floor New York, NY 10036 PROXY STATEMENT FOR THE PETROS PHARMACEUTICALS, INC. 2024 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON NOVEMBER 20, 2024 This Proxy Statement, along with the Notice of Annual Meeting of Stockholders, contains information about the 2024 Annual Meeting of Petros Pharmaceuticals, Inc., including any adjournments or postponements thereof. We are holding the Annual Meeting at 10 a.m. Eastern Time, on Wednesday, November 20, 2024, in virtual format at www.virtualshareholdermeeting.com/PTPI2024 . In this Proxy Statement, we refer to Petros Pharmaceuticals, Inc. as "Petros," "the Company," "we" and "us." This Proxy Statement relates to the solicitation of proxies by our Board of Directors for use at the Annual Meeting. On or about October 25,

View Full Filing

View this DEF 14A filing on SEC EDGAR